Takeda’s Entyvio snags second FDA approval as ‘subcutaneous option’ for Crohn’s disease
The FDA has approved subcutaneous administration of Takeda Pharmaceuticals’ Entyvio for maintenance therapy in adult patients with moderate-to-severe Crohn’s disease following induction therapy via IV administration of the biologic. Subcutaneous Entyvio (vedolizumab, Takeda Pharmaceuticals) was previously approved in 2023 for moderate-to-severe ulcerative colitis. The company noted